stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Trevi Therapeutics, Inc.

United States · NASDAQ: TRVI · Market cap: · P/E: · P/S:

Trevi Therapeutics is a small drug company developing an oral medicine called Haduvio to treat chronic cough in people with serious lung diseases.

Trevi Therapeutics is a clinical-stage biotech company trying to solve a problem that gets far less attention than it deserves: the kind of relentless, exhausting cough that never goes away. Its one big bet is a drug called Haduvio, an extended-release pill version of an old opioid painkiller called nalbuphine. The twist is that it's formulated to work in the body in a way that quiets the cough reflex without the sedation and abuse problems you'd expect from an opioid. The company is testing it mainly in people with serious scarring lung diseases — idiopathic pulmonary fibrosis (IPF) and other non-IPF interstitial lung diseases — where chronic cough is common, miserable, and has no approved treatment. It's also going after refractory chronic cough, a broader group of patients who cough for months or years with no clear cause and nothing that works.

Trevi Therapeutics, Inc. (TRVI) Haduvio (oral nalbuphine ER): line art illustration of an extended-release oral capsule labeled Haduvio
Haduvio capsules
Haduvio is an investigational oral capsule being studied to calm chronic cough.

The business model is the classic biotech gamble. Trevi doesn't sell anything yet. It spends money on clinical trials and stays alive on cash from investors, and its whole future hinges on whether Haduvio works safely in late-stage testing and then wins regulatory approval. If it does, the payoff could be large, because there's currently no drug approved specifically to treat chronic cough in these lung-disease patients — doctors can only offer workarounds. If the trials fail, the company has little else to fall back on, which is the harsh reality of a one-drug pipeline. That concentration is both the appeal and the danger. A single strong trial result can send a tiny biotech's value soaring; a single safety scare or failed endpoint can crush it. Trevi's strategy is to target the sickest, most underserved patients first, where the need is clearest and regulators may be more receptive, then expand. It's headquartered in Connecticut, which matters little to the story — what matters is the science and the cash runway.


For now, the company is a story about potential, not profits. Investors are effectively placing a bet on one molecule and one medical idea: that you can calm a runaway cough without the downsides of a traditional opioid. Watch the trial readouts, because that's where the entire business lives or dies.

Saved answer · last researched 16 Nov 2026